Newly diagnosed Multiple Myeloma is a blood cancer that starts in the bone‑marrow and can cause bone damage, fatigue, and infections. The trial evaluates a new therapy called AZD0120, which is a specially engineered cell treatment known as CAR T therapy, designed to recognize and attack cancer cells that carry the BCMA and CD19 markers. In the comparison arm, patients receive a combination of standard medicines that include bortezomib, lenalidomide, daratumumab, isatuximab and dexamethasone.
The purpose of the study is to determine whether a single infusion of the new cell therapy after an initial treatment period works better than staying on continuous standard therapy. All participants first receive an “induction” phase, which is an early round of treatment meant to quickly lower the amount of cancer. After this, one group receives the one‑time AZD0120 infusion, while the other group continues taking the standard medicines over time.
After the assigned treatment, participants are followed with regular doctor visits, blood tests, and imaging to check for signs of disease progression, which is measured as “progression‑free survival” (the time the cancer does not get worse). Additional checks look for a very deep response called “MRD negative complete response” (meaning tests cannot find any remaining cancer cells). Safety is also monitored through reports of side effects, vital signs, and laboratory results throughout the study period.
Denmark 
France 
Germany 
Italy 
Poland 
Spain 
Sweden 
